CLAIMS

1. Cells having expression and/or secretion of the pro-angiogenic factors VEGF, CXCL5 and IL-8 for use in preventing or treating an ischemic condition in a subject, the cells being non-embryonic stem, non-germ cells that express one or more of oct4, telomerase, rex-1, or rox-1 and can differentiate into cell types of at least two of endodermal, ectodermal, and mesodermal germ layers, wherein, prior to administration, said cells have been assayed for having expression and/or secretion of the pro-angiogenic factors VEGF, CXCL5 and IL-8.

2. The cells for the use of claim 1, wherein the cells are allogeneic.

3. The cells for the use of any one of claims 1 to 2, wherein the ischemic condition is a condition selected from the group consisting of acute myocardial infarction, chronic heart failure, peripheral vascular disease, stroke, chronic total occlusion, renal ischemia, and acute kidney injury.

4. The cells for the use of any of claims 1-3 wherein said subject is human.

5. A method for constructing a cell bank, said method comprising assaying cells for having expression and/or secretion of the pro-angiogenic factors VEGF, CXCL5 and IL-8, expanding and storing, for future administration to a subject, cells that have the expression and/or secretion of the pro-angiogenic factors VEGF, CXCL5 and IL-8, the cells being non-embryonic stem, non-germ cells that express one or more of oct4, telomerase, rex-1, or rox-1 and can differentiate into cell types of at least two of endodermal, ectodermal, and mesodermal germ layers.

6. An *in vitro* method for drug discovery, said method comprising exposing cells that have expression and/or secretion of the pro-angiogenic factors VEGF, CXCL5 and IL-8, to an agent to assess the effect of the agent on the ability of the cells to express and secrete the pro-angiogenic factors VEGF, CXCL5 and IL-8, the cells being non-embryonic stem, non-germ cells that express one or more of oct4, telomerase, rex-1, or rox-1 and/or can differentiate into cell types of at least two of endodermal, ectodermal, and mesodermal germ layers.

7. The method of claim 6, wherein said cells have been assayed for having expression and/or secretion of the pro-angiogenic factors VEGF, CXCL5 and IL-8.

8. An *in vitro* method for increasing the expression of the pro-angiogenic factors VEGF, CXCL5 and IL-8 in a stem cell, the method comprising exposing the cell to a combination of TNF-α, IL-1β, and IFNγ, or to a prostaglandin F analog wherein said cells are non-embryonic stem, non-germ cells that express one or more of oct4, telomerase, rex-1, or rox-1 and can differentiate into cell types of at least two of endodermal, ectodermal, and mesodermal germ layers, wherein the prostaglandin F analog is latanoprost.

9. The cells for the use of any one of claims 1 to 4 or the method of any one of claims 5 to 8, wherein the cells are multipotent progenitor cells.

10. The cells for the use of any one of claims 1 to 4 and 9, or the method of any one of claims 5 to 9, wherein the cells express telomerase.

11. The cells for the use of any one of claims 1 to 4 and 9, or the method of any one of claims 5 to 9, wherein the cells express oct4.

12. The cells for the use of any one of claims 1 to 4 and 9, or the method of any one of claims 5 to 9, wherein the cells express telomerase and oct4.

13. The cells for the use of any one of claims 1 to 4 and 9 to 12, or the method of any one of claims 5 to 12, wherein the cells can differentiate into cell types of endodermal, ectodermal, and mesodermal germ layers.

14. The cells for the use of any one of claims 1 to 4 and 9 to 13, or the method of any one of claims 5 to 13, wherein the cells are human cells.

15. The cells for the use of any one of claims 1 to 4 and 9 to 14, or the method of any one of claims 5 to 14, wherein the cells are derived from bone marrow.